Amyloid precursor protein (APP) gives rise to the amyloid-β peptide and thus has a key role
in the pathogenesis of Alzheimer disease. By contrast, the physiological functions of APP …

Alzheimer disease (AD) prevention trials hold the promise to delay or prevent cognitive
decline and dementia onset by intervening before significant neuronal damage occurs. In …

Diseases of infection, of neurodegeneration (such as Alzheimer's and Parkinson's
diseases), and of malignancy (cancers) have complex and varied causative factors. Modern …

Alzheimer's disease (AD) is an age-associated neurodegenerative disease that is reaching
epidemic proportions as a result of the aging of the world's population. Impressive gains in …

Monitoring effects of disease or therapeutic intervention on brain function is increasingly
important for clinical trials, albeit hampered by inter-individual variability and subtle effects …

Rationale Alzheimer's disease (AD) is a neurodegenerative disorder with irreversible loss of
intellectual abilities. Current therapies for AD are still insufficient. Objective In this study, the …

Processing of amyloid-β (Aβ) precursor protein (APP) by γ-secretase produces multiple
species of Aβ: Aβ40, short Aβ peptides (Aβ37–39), and longer Aβ peptides (Aβ42–43). γ …

Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disorder
characterized by the synaptic and neuronal loss, which results in cognitive impairment in …

Immunoproteostasis is a term used to reflect interactions between the immune system and
the proteinopathies that are presumptive" triggers" of many neurodegenerative disorders …

The genetic analysis of complex disorders has undoubtedly led to the identification of a
wealth of associations between genes and specific traits. However, moving from genetics to …